1. Search Result
Search Result
Results for "

Gastric Inhibitory Peptide (GIP), human

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

8

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0276
    GIP, human
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human

    Insulin Receptor Metabolic Disease
    GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human
  • HY-P0276A
    GIP, human TFA
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human TFA

    Insulin Receptor Metabolic Disease
    GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human TFA
  • HY-P3580A

    human N-acetyl GIP TFA

    Insulin Receptor Metabolic Disease Endocrinology
    Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
    Acetyl Gastric Inhibitory Peptide (human) (TFA)
  • HY-P3584A

    (Pro3) Gastric Inhibitory Peptide, human TFA

    Insulin Receptor Metabolic Disease
    (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human TFA
  • HY-P3584

    (Pro3) Gastric Inhibitory Peptide, human

    Insulin Receptor Metabolic Disease
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human
  • HY-P3580

    human N-acetyl GIP

    Insulin Receptor Metabolic Disease Endocrinology
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-P3577

    Insulin Receptor Metabolic Disease
    [Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .
    [Tyr0] Gastric Inhibitory Peptide (23-42), human
  • HY-P0165B

    ITM077 acetate; R1583 acetate; BIM51077 acetate

    GLP Receptor Metabolic Disease
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
    Taspoglutide acetate